β-Amyloid (17-40) peptide
Not For Human Use, Lab Use Only.
Cat.#: 314653
Price 234.70 USD
-
Product Name
β-Amyloid (17-40) peptide
-
Documents
Batch to batch variation of the purity
-
Sequence Shortening
LVFFAEDVGSNKGAIIGLMVGGVV
-
Sequence
Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
-
Length (aa)
24
-
Peptide Purity (HPLC)
96%
-
Molecular Formula
C110H178N26O31S
-
Molecular Weight
2392.86
-
CAS No.
156790-69-1
-
Source
Synthetic
-
Form
Powder
-
Description
β-Amyloid (17-40), also known as the p3 peptide, is an N-terminally truncated fragment of the amyloid-β peptide produced through alternative processing of the amyloid-β protein precursor by α- and γ-secretases. This peptide lacks the hydrophilic N-terminal region of full-length amyloid-β and is composed largely of hydrophobic residues. The aggregation-prone regions predicted for amyloid-β (residues 17-22 and 30-42) are entirely contained within the p3 sequence, suggesting that this fragment retains significant self-assembly propensity.
Biophysical studies have shown that p3 can form fibril-like structures with morphologies that differ from those of full-length amyloid-β, including shorter fibril lengths, narrower diameters, and greater heterogeneity. Secondary structure analyses indicate that p3 adopts predominantly β-sheet character under physiological conditions, and kinetic studies have revealed that p3 aggregates more rapidly than amyloid-β, with substantially higher sedimentation of aggregates. The peptide has been detected in amyloid plaques from postmortem brain tissue, where it constitutes a major component of diffuse plaques. Additionally, p3 has been reported to form annular, channel-like structures in lipid bilayers and to elicit pro-inflammatory cytokine production, indicating that it exhibits biological activities comparable to those of full-length amyloid-β.
-
Storage Guidelines
Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides
-
References
- Kuhn AJ, Raskatov J. Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?1. J Alzheimers Dis. 2020;74(1):43-53. doi: 10.3233/JAD-191201. PMID: 32176648; PMCID: PMC7443050.
-
About TFA salt
Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.
Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.
Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.
In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.
- Molar Concentration Calculator
- Dilution Calculator
- Percent Concentration Calculator
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Related Products / Services
• Peptide Services: NovoPro's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.
• Standard Peptide Synthesis: NovoPro offers quality peptides at the most competitive prices in the industry, starting at $3.20 per amino acid. NovoPro provides PepBox – Automatic Quote Tool for online price calculation.
• Peptide Modifications: NovoPro offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"